Results 161 to 170 of about 327,168 (302)

Targeting PRKCN, an Essential Driver Orchestrating mTOR‐IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma

open access: yesAdvanced Science, EarlyView.
Constitutive PRKCN expression is driven by super‐enhancers and modulated by NF‐κB signaling in multiple myeloma (MM). PRKCN activates mTORC1/2‐IRF4 signaling axis and favors tumor cell growth independently of its kinase activity. IRF4 reciprocally promotes PRKCN transcription, creating a feed‐forward loop.
Koukou Tang   +12 more
wiley   +1 more source

Site-Specific PEGylation at Residue 86 Improves Pharmacokinetic Properties of Interferon α-2b. [PDF]

open access: yesIran J Biotechnol
Alboshokeh MA   +5 more
europepmc   +1 more source

Intelligent Thermo‐Self‐Limited Magnetothermia with Heat‐Triggered TERT Silencing for Precision Synergetic Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Telomerase reverse transcriptase (TERT) mRNA induces DNA self‐assembly in cancer cells, boosting the nanoplatform's magnetothermal properties. This magnetothermia then activates the Hsp70 promoter, initiating siRNA synthesis to silence the TERT gene, enhancing cancer treatment.
Liang Zhang   +9 more
wiley   +1 more source

Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio‐Immunotherapy

open access: yesAdvanced Science, EarlyView.
A CD44‐targeted MnPt bimetallic nanozyme (HD@MnO2) integrates multienzyme‐like activity with cGAS–STING activation to boost radio‐immunotherapy. Through cascade biocatalysis, it depletes glutathione, relieves hypoxia, and amplifies ROS, enhancing radiotherapy‐induced DNA damage and immunogenic cell death. The nanozyme promotes dendritic cell maturation
Wenyi Zhang   +8 more
wiley   +1 more source

PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
The PBAP‐gE complex anchors gE antigen to PD‐L1 on tumor cells. Vaccine‐induced anti‐gE antibodies simultaneously engage FcγRIIIa on NK cells and tumor‐bound PBAP‐gE, triggering NK cell activation and antibody‐dependent cellular cytotoxicity, thereby selectively eliminating PD‐L1–expressing tumor cells.
Huixin Gao   +24 more
wiley   +1 more source

Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma

open access: yesAdvanced Science, EarlyView.
Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian   +7 more
wiley   +1 more source

DADA Enhances CD8+ T Cell Stemness to Improve Anti‐Tumor Immunity and Immunotherapy Efficacy

open access: yesAdvanced Science, EarlyView.
Diisopropylamine dichloroacetate (DADA) enhances CD8+ T cell stemness by improving OXPHOS and mitochondrial fitness in a PDK1‐depenpendent manner. This metabolic shift strengthens CD8+ T cell anti‐tumor immunity, improves responses to PD‐1 blockade, and endows CAR‐T cells with prolonged persistence and resistance to terminal exhaustion, highlighting a ...
Mingyue Bi   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy